HEL Cells
General information
Description | HEL cells are a human erythroleukemia cell line that was established from the peripheral blood of a 30-year-old man with erythroleukemia in relapse after treatment for Hodgkin lymphoma in 1980. HEL cells are capable of spontaneous and induced globin synthesis, producing mainly G gamma and A gamma chains. These cells also express embryonic chains (epsilon, zeta) and alpha chains in minimal amounts, while beta chains are undetectable. HEL cells are round, large to occasionally giant polynucleated, single cells in suspension, with a few cells adherent. The expression of mutated JAK2 has been confirmed in these cells by RT-PCR and sequencing. HEL cells express several cell surface markers, including CD3-, CD13+, CD14-, CD19-, CD33+, CD41a+, CD71+, and CD235a+. According to research, hydroxyurea, a medicine routinely used to treat a variety of cancers, including erythroleukemia, may also regulate the death of HEL cells. HEL cell apoptosis produced by hydroxyurea may be connected to HEL cell terminal differentiation. Additionally, earlier research has shown that hydroxyurea may be crucial in controlling HEL cell proliferation and differentiation. |
---|---|
Organism | Human |
Tissue | Peripheral blood |
Disease | Erythroleukemia |
Synonyms | Hel, GM06141, GM06141B, Human ErythroLeukemia |
Characteristics
Age | 30 years |
---|---|
Gender | Male |
Ethnicity | European |
Morphology | Rounded |
Growth properties | Adherent/suspension |
Identifiers / Biosafety / Citation
Citation | HEL (Cytion catalog number 305022) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 36 hours |
Subculturing | Gather the suspension cells in a 15 ml tube and gently wash the adherent cells with PBS lacking calcium and magnesium (use 3-5 ml for T25 flasks and 5-10 ml for T75 flasks). Apply Accutase (1-2 ml for T25 flasks, 2.5 ml for T75 flasks) ensuring full coverage of the cell layer. Allow the cells to incubate at room temperature for 10 minutes. Following incubation, combine and centrifuge both the suspension and adherent cells. After centrifugation, carefully resuspend the cell pellet and transfer the cell suspension into new flasks containing fresh medium. |
Split ratio | 1:2 to 1:4 |
Fluid renewal | 2 to 3 times per week |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile |
Amelogenin: x,x
CSF1PO: 10,11
D13S317: 9
D16S539: 11
D5S818: 11
D7S820: 7
TH01: 7
TPOX: 11
vWA: 14,17
D3S1358: 15
D21S11: 29,30.2,31.2
D18S51: 12,16
Penta E: 13,18
Penta D: 11,13
D8S1179: 13,15
FGA: 21,22,23
D6S1043: 11,13
D2S1338: 18,19
D12S391: 18,21
D19S433: 11,13
|